Astria Therapeutics, Inc.

The company is a biopharmaceutical company focused on discovering, developing, and commercializing new treatments for allergic and immunological diseases. Its primary goal is to create first-choice therapies that enhance the health and outcomes for patients with these conditions. The company's lead product candidate is navenibart, previously known as STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein. Navenibart is currently in clinical development for treating hereditary angioedema (HAE), a rare, debilitating, and potentially life-threatening disease. The U.S. Food and Drug Administration (FDA) has granted Fast Track and Orphan Drug designations to navenibart for HAE treatment, and the European Commission has granted Orphan Medicinal Product Designation for the same indication. In February 2025, the company started a Phase 3 trial for navenibart called ALPHA-ORBIT. The company's second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist in clinical development for atopic dermatitis (AD), an immune disorder characterized by skin barrier dysfunction and itching. These programs aim to advance a pipeline of products with distinct profiles based on validated mechanisms.